{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:30:23Z","timestamp":1781019023623,"version":"3.54.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K24AI104830"],"award-info":[{"award-number":["K24AI104830"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UL1 TR001450"],"award-info":[{"award-number":["UL1 TR001450"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mycobacterium abscessus is a virulent human pathogen. Treatment is complex and often poorly tolerated with suboptimal rates of eradication, highlighting the need for improved therapeutics. This study reports clinical experience with omadacycline for treatment of M abscessus infections at five large nontuberculous mycobacterial (NTM) disease clinics across the United States to better understand long-term safety and tolerability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a multicenter retrospective chart review of adults with M abscessus infections. All patients treated with omadacycline as part of a multidrug therapeutic regimen through December 2021 were included. Clinical data from time of omadacycline initiation and up to 12 months of follow-up were collected. Descriptive statistics were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Analysis included 117 patients. Among patients with M abscessus isolate subspeciation, 58 of 71 (81.7%) were M abscessus spp abscessus. In isolates with reported drug susceptibility testing, 15 of 70 (21.4%) had confirmed susceptibility to macrolides. The most common site of infection was lungs. Median duration omadacycline treatment was 8 months (range, 0.25\u201333 months; interquartile range, 4\u201315 months). Omadacycline was discontinued in 60 patients (51.3%); 20 completed planned treatment course, 23 experienced intolerance or adverse event leading to drug cessation, and 17 stopped due to cost, death (unrelated to NTM infection or therapy), or another reason. In those with pulmonary disease, 44 of 95 (46%) had 1 or more negative cultures at time of final microbiological assessment, with 17 of 95 (18%) achieving culture conversion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study reports data supporting long-term safety and tolerability of omadacycline along with signal of effectiveness in treatment of M abscessus infections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad335","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T18:52:13Z","timestamp":1688410333000},"source":"Crossref","is-referenced-by-count":41,"title":["Long-term Safety and Tolerability of Omadacycline for the Treatment of <i>Mycobacterium abscessus<\/i> Infections"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-8505","authenticated-orcid":false,"given":"Christina M","family":"Mingora","sequence":"first","affiliation":[{"name":"Medical University of South Carolina , Charleston, South Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Bullington","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina , Charleston, South Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige E","family":"Faasuamalie","sequence":"additional","affiliation":[{"name":"Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrah","family":"Levin","sequence":"additional","affiliation":[{"name":"National Jewish Health and University of Colorado School of Medicine , Denver, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Porter","sequence":"additional","affiliation":[{"name":"New York University Grossman School of Medicine , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Stadnik","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara D","family":"Varley","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Addrizzo-Harris","sequence":"additional","affiliation":[{"name":"New York University Grossman School of Medicine , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L","family":"Daley","sequence":"additional","affiliation":[{"name":"National Jewish Health and University of Colorado School of Medicine , Denver, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth N","family":"Olivier","sequence":"additional","affiliation":[{"name":"Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E","family":"Dorman","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina , Charleston, South Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A","family":"Flume","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina , Charleston, South Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"2023082214065584900_ofad335-B1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease","volume":"161","author":"Griffith","year":"2022","journal-title":"Chest"},{"key":"2023082214065584900_ofad335-B2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023082214065584900_ofad335-B3","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02522-18","article-title":"In vitro activities of omadacycline against rapidly growing mycobacteria","volume":"63","author":"Shoen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023082214065584900_ofad335-B4","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O'Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2023082214065584900_ofad335-B5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O'Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"2023082214065584900_ofad335-B6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"2023082214065584900_ofad335-B7","volume-title":"Nuzyra (omadacycline) [package insert]","year":"2021"},{"key":"2023082214065584900_ofad335-B8","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023082214065584900_ofad335-B9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01947-20","article-title":"In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023082214065584900_ofad335-B10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00470-19","article-title":"In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023082214065584900_ofad335-B11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023082214065584900_ofad335-B12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023082214065584900_ofad335-B13","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa415","article-title":"Omadacycline for the treatment of Mycobacterium abscessus disease: a case series","volume":"7","author":"Pearson","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023082214065584900_ofad335-B14","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ijid.2022.06.061","article-title":"Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series","volume":"122","author":"Duah","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2023082214065584900_ofad335-B15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2023082214065584900_ofad335-B16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2023082214065584900_ofad335-B17","volume-title":"Tygacil (tigacycline) [package insert]","year":"2021"},{"key":"2023082214065584900_ofad335-B18","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/cid\/ciz398","article-title":"An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic","volume":"69","author":"Opal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023082214065584900_ofad335-B19","doi-asserted-by":"crossref","first-page":"S746","DOI":"10.1093\/ofid\/ofaa439.1669","article-title":"Relationship between culture conversion and clinical outcomes in patients with Mycobacterium abscessus (MAB) lung disease: a systematic literature review","volume":"7","author":"Flume","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023082214065584900_ofad335-B20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.5588\/ijtld.14.0134","article-title":"Advances in the management of pulmonary disease due to Mycobacterium abscessus complex","volume":"18","author":"Koh","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023082214065584900_ofad335-B21","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1128\/JCM.01688-08","article-title":"Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii","volume":"47","author":"Zelazny","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2023082214065584900_ofad335-B22","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2022.115882","article-title":"In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States","volume":"105","author":"Hunkins","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023082214065584900_ofad335-B23","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102269","article-title":"Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"137","author":"Shankar","year":"2022","journal-title":"Tuberculosis (Edinb)"},{"key":"2023082214065584900_ofad335-B24","article-title":"In vitro antimicrobial activities of tigecycline, eravacycline, omadacycline, and sarecycline against rapidly growing mycobacteria","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2023082214065584900_ofad335-B25","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1128\/AAC.03112-15","article-title":"Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad335\/50789556\/ofad335.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/7\/ofad335\/51218273\/ofad335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/7\/ofad335\/51218273\/ofad335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T15:57:19Z","timestamp":1692719839000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad335\/7218331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad335","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,7,1]]},"article-number":"ofad335"}}